Filtered By:
Management: Funding
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 373 results found since Jan 2013.
A potential breakthrough for peanut allergy treatment
Peanut allergies are among the most rapidly growing food allergies in the United States. Millions of children are currently living with the condition, with new cases being diagnosed daily. (A recent study shows the number of reported peanut allergies tripled in just over a decade.) And because allergic reactions to peanuts tend to be the most severe—80 to 95 percent of all food allergy deaths are peanut or tree nut related—the trend is a serious cause for concern.
But a small pilot study published by the Journal of Allergy and Clinical Immunology, may offer hope for the hundred of thousands of families living with the ...
Source: Thrive, Children's Hospital Boston - November 4, 2013 Category: Pediatrics Authors: Tripp Underwood Tags: All posts Food allergies Kids' safety Milk allergies Parenting clinical trial food allergy Dale Umetsu Lynda Schneider peanut allergies Rima Rachid Source Type: news
Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial
In this study, we developed a practical approach to overcome the second wave of the allergic epidemic caused by food allergy. Funding Ministry of Health, Labour and Welfare, and National Centre for Child Health and Development, Japan.
Source: The Lancet - December 8, 2016 Category: Journals (General) Source Type: research
NIH designates $42.7 million for food allergy research consortium
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health intends to award $42.7 million over seven years to the Consortium of Food Allergy Research (CoFAR) so it may continue evaluating new approaches to treat food allergy. Established in 2005, the CoFAR has been continuously funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. The first year of funding has been awarded, and awards will be made in subsequent years based on the availability of funds.
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news
State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneous
IgE-mediated food allergy is a global health problem that affects millions of persons and affects every aspect of life for the patient. Developing effective treatment strategies to augment current practice standards of strict dietary avoidance of antigens and availability of self-injectable epinephrine has been a major focus of research teams, advocacy groups, funding agencies, and patients and their families. Significant progress has been made through the development of allergen-specific immunotherapy encompassing 3 major forms of treatment: oral, sublingual, and epicutaneous immunotherapy. These therapies are in various ...
Source: Journal of Allergy and Clinical Immunology - February 1, 2014 Category: Allergy & Immunology Authors: Stacie M. Jones, A. Wesley Burks, Christophe Dupont Tags: Current perspectives Source Type: research
News & Notes
The AAAAI is pleased to announce the 2014 recipients of the AAAAI research and training awards, the AAAAI abstract and career program scholarships, and the Allergy, Asthma & Immunology Education and Research Organization, Inc. (ARTrust™) awards presented at the 2014 Annual Meeting. These programs total almost $1,300,000 in funding and represent the ongoing commitment of the AAAAI and its industry partners and the ARTrust toward the future of allergy/immunology.
Source: Journal of Allergy and Clinical Immunology - March 1, 2014 Category: Allergy & Immunology Tags: Reader services Source Type: research
Erratum
In the article entitled “Immunodominance in allergic T-cell reactivity to Japanese cedar in different geographic cohorts” (Ann Allergy Asthma Immunol 2016;117:680-689), acknowledgment of funding sources was inadvertently omitted from the article. Funding for the article was provided in part by ALK-Abello A/S (Horsholm, Denmark) and with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under grant number U19 AI100275.
Source: Annals of Allergy, Asthma and Immunology - January 15, 2017 Category: Allergy & Immunology Tags: Erratum Source Type: research
Lyndra gets boost for drug delivery platform from U.S. allergy institute
Lyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the formulation and preclinical development of a once-weekly oral HIV treatment.
The Watertown, Mass.-based company makes use of a sustained-release technology developed by Robert Langer at the Massachusetts Institute of Technology. A star-shaped pill loaded with drugs remains in the gastric cavity after it’s been swallowed for a pre-determined length of time. After the drugs have been released, the pill splits into small pieces and saf...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Research & Development lyndra Source Type: news
Research resources for tuberculosis at the National Institute of Allergy and Infectious Diseases
Summary: Global control of tuberculosis (TB) requires the participation of multiple stakeholders that cross the spectrum of biomedical research, product development, and implementation and operational research. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), plays a critical role in TB biomedical research and product development by directly supporting and leveraging other funding support strategies and providing research resources to facilitate the translation of knowledge about TB into strategies and tools to more effectively combat disease. The primary m...
Source: Tuberculosis - February 5, 2013 Category: Respiratory Medicine Authors: NIH, DMID TB program Tags: Special Issue Articles Source Type: research
Correction
With regard to the article in the June 2014 issue entitled “Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency” (J Allergy Clin Immunol 2014;133:1660-6), the authors report an incorrect funding statement, which should read as follows: W.Q. and H.G. are supported by GOSHCC trustees. This research was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.
Source: Journal of Allergy and Clinical Immunology - March 31, 2016 Category: Allergy & Immunology Tags: Correction Source Type: research
Has EpiPen Price Gouger Mylan Silenced Allergy Advocates?
Prominent allergy advocacy groups have yet to criticize pharmaceutical maker Mylan for its 480% price hike on lifesaving EpiPens. Is it because they receive funding from Mylan?
Source: Forbes.com Healthcare News - August 25, 2016 Category: Pharmaceuticals Authors: Nancy Fink Huehnergarth Source Type: news
Correction
With regard to the article in the April 2017 issue entitled ‘‘Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173” (J Allergy Clin Immunol 2017;139:1396-9), the authors wish to amend the funding support section to state “A portion of this study was supported by grants from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Republic of Korea (HI12C0066; to J.-H.C.), and the Brain Research Program through th...
Source: Journal of Allergy and Clinical Immunology - June 1, 2017 Category: Allergy & Immunology Tags: Correction Source Type: research
Billionaire Koch brother donates $10M to Stanford children's hospital to back allergy research
Koch Industries executive David Koch and his wife have donated $10 million to advance allergy research at Stanford. The funding will allow researchers to grow the team at its new campus and run more clinical trials.
Source: bizjournals.com Health Care News Headlines - June 16, 2017 Category: Health Management Authors: Antoinette Siu Source Type: news
